Bayer Brushes Off Xarelto Study Device Defect Worries
This article was originally published in Scrip
Executive Summary
Bayer AG said it believes top-selling drug Xarelto (rivaroxaban) "remains a reasonable alternative to warfarin" despite worries a defective blood-clotting test device affected a key trial studying the novel anti-blood clotting pill used to underpin its approval for treating patients with irregular heartbeat.